ASCO 2022
Oral Presentation
Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT – EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification
Vicky Makker, Memorial Sloan Kettering Cancer Center
5511
Clinical Science Symposium/Molecular-Based Treatment for Endometrial Cancer
Tuesday, June 7, 2022, 8:00 a.m. – 9:30 a.m. CDT
Poster Presentations
A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis
Haris Ali, City of Hope
7060, Poster 29
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Saturday, June 4, 2022, 8:00 a.m. – 11:00 a.m. CDT
Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS)
Abdulazeez Salawu, University Health Network
11563, Poster 467
Sarcoma
Sunday, June 5, 2022, 8:00 a.m. – 11:00 a.m. CDT
Digital monitoring and assessments in patients with glioblastoma
Yasaman Damestani, Karyopharm Therapeutics, Inc.
2045, Poster 383
Central Nervous System Tumors
Sunday, June 5, 2022, 8:00 a.m. – 11:00 a.m. CDT
Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.
Blessie Nelson, The University of Texas MD Anderson Cancer Center
3108, Poster 100
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sunday, June 5, 2022, 8:00 a.m. – 11:00 a.m. CDT
Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience.
Omar Alhalabi
Blessie Nelson, The University of Texas MD Anderson Cancer Center
4551, Poster 42
Genitourinary Cancer—Kidney and Bladder
Saturday, June 4, 2022, 1:15 p.m. – 4:15 p.m. CDT